Table 4.
Hazards ratios (HR) and 95% CI of inflammatory markers for obesity-related cancers by obesity, NSAID use and gender.
| Log-Transformed Inflammatory Markers
|
Tertiles of Inflammatory Markers
|
|||||
|---|---|---|---|---|---|---|
| Pinteraction | T1 | T2 | T3 | Pinteraction | ||
|
|
|
|||||
| CRP (ug/mL), updated | ||||||
| Obesity | ||||||
| BMI <30, Cases (PY *) | 119 (18,808) | 0.04 | 40 (7,128) | 31 (6,319) | 48 (5,361) | 0.11 |
| RR (95% CI) | 1.21 (1.02,1.44) | 1.00 | 0.84 (0.52,1.34) | 1.64 (1.06,2.52) | ||
| BMI ≥30, Cases (PY) | 45 (6,598) | 13 (1,351) | 15 (2,151) | 17 (3,096) | ||
| RR (95% CI) | 0.76 (0.58,1.00) | 1.00 | 0.73 (0.35,1.56) | 0.56 (0.27,1.17) | ||
| NSAID Use | ||||||
| Yes, Cases (PY) | 130 (20,773) | 0.85 | 41 (6,978) | 39 (6,939) | 50 (6,855) | 0.60 |
| RR (95% CI) | 1.08 (0.92,1.28) | 1.00 | 0.93 (0.59,1.44) | 1.24 (0.80,1.90) | ||
| No, Cases (PY) | 34 (4,633) | 12 (1,501) | 7 (1,530) | 15 (1,602) | ||
| RR (95% CI) | 1.03 (0.75,1.42) | 1.00 | 0.56 (0.21,1.44) | 1.20 (0.53,2.69) | ||
| Gender | ||||||
| Men, Cases (PY) | 93 (10,897) | 0.29 | 34 (4,042) | 27 (3,849) | 32 (3,006) | 0.24 |
| RR (95% CI) | 0.99 (0.81,1.20) | 1.00 | 0.75 (0.45,1.25) | 1.12 (0.67,1.85) | ||
| Women, Cases (PY) | 71 (14,509) | 19 (4,438) | 19 (4,620) | 33 (5,451) | ||
| RR (95% CI) | 1.14 (0.91,1.43) | 1.00 | 0.90 (0.47,1.71) | 1.29 (0.72,2.33) | ||
| IL-6 (pg/mL), updated | ||||||
| Obesity | ||||||
| BMI <30, Cases (PY) | 116 (18,948) | 0.22 | 40 (7,177) | 43 (6,154) | 33 (5,617) | 0.21 |
| RR (95% CI) | 0.99 (0.75,1.31) | 1.00 | 1.14 (0.73,1.76) | 0.97 (0.61,1.56) | ||
| BMI ≥30, Cases (PY) | 49 (6,679) | 12 (1,394) | 19 (2,422) | 18 (2,863) | ||
| RR (95% CI) | 0.67 (0.40,1.14) | 1.00 | 0.79 (0.37,1.68) | 0.61 (0.28,1.31) | ||
| NSAID Use | ||||||
| Yes, Cases (PY) | 132 (20,947) | 0.96 | 40 (6,850) | 48 (7,069) | 44 (7,028) | 0.35 |
| RR (95% CI) | 0.90 (0.68,1.19) | 1.00 | 1.05 (0.69,1.62) | 0.94 (0.60,1.47) | ||
| No, Cases (PY) | 33 (4,680) | 12 (1,721) | 14 (1,508) | 7 (1,452) | ||
| RR (95% CI) | 1.00 (0.59,1.67) | 1.00 | 1.22 (0.56,2.70) | 0.60 (0.23,1.58) | ||
| Gender | ||||||
| Men, Cases (PY) | 94 (11,010) | 0.70 | 27 (3,226) | 39 (3,876) | 28 (3,908) | 0.53 |
| RR (95% CI) | 0.90 (0.65,1.25) | 1.00 | 1.18 (0.71,1.94) | 0.84 (0.49,1.45) | ||
| Women, Cases (PY) | 71 (14,617) | 25 (5,344) | 23 (4,700) | 23 (4,572) | ||
| RR (95% CI) | 0.89 (0.61,1.30) | 1.00 | 0.94 (0.52,1.67) | 0.93 (0.51,1.70) | ||
| TNF-α (pg/mL), baseline | ||||||
| Obesity | ||||||
| BMI <30, Cases (PY) | 109 (17,830) | 0.64 | 44 (6,340) | 33 (6,049) | 32 (5,441) | 0.64 |
| RR (95% CI) | 1.01 (0.62,1.65) | 1.00 | 0.79 (0.50,1.26) | 0.90 (0.56,1.43) | ||
| BMI ≥30, Cases (PY) | 46 (6,249) | 15 (2,223) | 21 (2,058) | 10 (1,967) | ||
| RR (95% CI) | 1.00 (0.46,2.17) | 1.00 | 1.62 (0.82,3.20) | 0.80 (0.35,1.83) | ||
| NSAID Use | ||||||
| Yes, Cases (PY) | 123 (19,653) | 0.26 | 43 (7,075) | 45 (6,628) | 35 (5,950) | 0.09 |
| RR (95% CI) | 1.12 (0.70,1.80) | 1.00 | 1.13 (0.74,1.73) | 1.00 (0.63,1.59) | ||
| No, Cases (PY) | 32 (4,427) | 16 (1,489) | 9 (1,479) | 7 (1,458) | ||
| RR (95% CI) | 0.62 (0.26,1.48) | 1.00 | 0.60 (0.26,1.39) | 0.51 (0.20,1.31) | ||
| Gender | ||||||
| Men, Cases (PY) | 85 (10,363) | 0.96 | 29 (3,374) | 34 (3,468) | 22 (3,521) | 0.78 |
| RR (95% CI) | 0.91 (0.52,1.60) | 1.00 | 1.21 (0.73,2.01) | 0.84 (0.47,1.49) | ||
| Women, Cases (PY) | 70 (13,717) | 30 (5,190) | 20 (4,640) | 20 (3,887) | ||
| RR (95% CI) | 1.05 (0.56,1.97) | 1.00 | 0.67 (0.37,1.19) | 0.92 (0.51,1.66) | ||
*
PY: person-years.
Models were adjusted for age in years (continuous), race (black/white), gender, site, body mass index (kg/m2), smoking (never, former <20 pack-years, former ≥20 pack-years, current <20 pack-years, current ≥20 pack-years), current diabetes, NSAID use (yes/no), baseline physical activity (0, 0–499.9, 500–999.9, 1,000–1,499.9, 1500–1,999.9, >2,000 Kcal/week) and alcohol consumption (no consumption in the past year, <1 drink/week, 1–7 drinks/week, >1 drinks/day).